Key result
Study lacks quantitative data comparing ARBs and ACEIs for dementia and mortality risk.
Why the study?
ARBs and ACEIs may differentially affect dementia risk by targeting distinct components of the renin-angiotensin system and through variations in blood-brain barrier permeability.
Does ARB-based antihypertensive therapy reduce dementia and mortality risk compared to ACEI-based therapy in individuals initiating antihypertensive therapy?
Cohort
Does ARB-based antihypertensive therapy reduce dementia and mortality risk compared to ACEI-based therapy in individuals initiating antihypertensive therapy?
Observational ARB vs ACEI data on dementia risk by BBB permeability should not change practice; leaves open confirmation in trials.
Angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) may differentially affect dementia risk by targeting distinct components of the renin-angiotensin system and through variations in their ability to cross the blood-brain barrier (BBB). This study compared the long-term risks of dementia and dementia-free mortality among individuals initiating ARBs vs ACEIs, stratified by BBB permeability.
No takes yet. Share an insight, caveat, or question.
Andrews et al. (2026) conducted a cohort in Hypertension. ARB-based antihypertensive therapy vs. ACEI-based antihypertensive therapy was evaluated on Long-term risks of dementia and dementia-free mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: